HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-0019v1 30/7/1834    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krzyzanowska, K. Articles by Schernthaner, G. Search for Related Content PubMed PubMed Citation Articles by Krzyzanowska, K. Articles by Schernthaner, G. Social Bookmarking                What's this?

Asymmetric Dimethylarginine Predicts Cardiovascular Events in Patients With Type 2 Diabetes

¹ Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria
² Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria

Address correspondence and reprint requests to Dr. Katarzyna Krzyzanowska, MD, Department of Internal Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria. E-mail: katarzyna.krzyzanowska{at}wienkav.at

OBJECTIVE— Circulating concentrations of an endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), are elevated in patients with increased cardiovascular risk. We hypothesized that ADMA predicts cardiovascular events and enhances risk prediction independent of established risk markers in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS— This prospective cohort study included 125 patients with type 2 diabetes. ADMA, L-arginine, high-sensitivity C-reactive protein (CRP), and routine clinical parameters were determined at baseline. First occurrence of cardiovascular events (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, carotid revascularization, or all-cause mortality) was defined as a composite end point.

RESULTS— During a median follow-up of 21 (interquartile range 11–27) months, 84 events occurred in 48 patients. According to multivariate Cox regression analysis, patients with baseline ADMA or CRP in the highest tertile had a significantly increased hazard ratio for incident cardiovascular events compared with those with ADMA or CRP in tertile 1 (2.37 [95% CI 1.05–5.35], P = 0.038, and 3.63 [1.59–8.28], P = 0.002). Assessing the joint effect of ADMA and CRP revealed that patients with either ADMA or CRP or both in the highest tertile had increased hazard ratios for cardiovascular events compared with patients with neither ADMA nor CRP in the highest tertile before and after adjustment for possible confounders (hazard ratio 4.59 [95% CI 2.07–10.15], P < 0.001).

CONCLUSIONS— ADMA predicted cardiovascular events and enhanced the predictive role of CRP in patients with type 2 diabetes. ADMA therefore could improve cardiovascular risk assessment in patients with type 2 diabetes.

Abbreviations: ADMA, asymmetric dimethylarginine • CRP, C-reactive protein

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W. H. Wilson Tang, W. Tong, K. Shrestha, Z. Wang, B. S. Levison, B. Delfraino, B. Hu, R. W. Troughton, A. L. Klein, and S. L. Hazen Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure Eur. Heart J., October 2, 2008; 29(20): 2506 - 2513. [Abstract] [Full Text] [PDF]

				T. Leong, D. Zylberstein, I. Graham, L. Lissner, D. Ward, J. Fogarty, C. Bengtsson, C. Bjorkelund, D. Thelle, and for The Swedish-Irish-Norwegian (SIN) Collaboratio Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 961 - 967. [Abstract] [Full Text] [PDF]

				G. Schernthaner Kidney disease in diabetology: lessons from 2007 Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1112 - 1115. [Full Text] [PDF]

				M. Lajer, L. Tarnow, A. Jorsal, T. Teerlink, H.-H. Parving, and P. Rossing Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy Diabetes Care, April 1, 2008; 31(4): 747 - 752. [Abstract] [Full Text] [PDF]

				G. Schernthaner and J. M. Morton Bariatric Surgery in Patients With Morbid Obesity and Type 2 Diabetes Diabetes Care, February 1, 2008; 31(Supplement_2): S297 - S302. [Full Text] [PDF]

				D. Heutling, H. Schulz, I. Nickel, J. Kleinstein, P. Kaltwasser, S. Westphal, F. Mittermayer, M. Wolzt, K. Krzyzanowska, H. Randeva, et al. Asymmetrical Dimethylarginine, Inflammatory and Metabolic Parameters in Women with Polycystic Ovary Syndrome before and after Metformin Treatment J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 82 - 90. [Abstract] [Full Text] [PDF]